More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis

Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review (ICER). The principal objection to ICER r...

Descripción completa

Detalles Bibliográficos
Autor principal: Langley, Paul C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Minnesota Libraries Publishing 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132526/
https://www.ncbi.nlm.nih.gov/pubmed/34017631
http://dx.doi.org/10.24926/iip.v11i1.2402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132526/
https://www.ncbi.nlm.nih.gov/pubmed/34017631
http://dx.doi.org/10.24926/iip.v11i1.2402

Ejemplares similares